key: cord-0774042-as8hve1s
authors: Cheedarla, Narayanaiah; Verkerke, Hans P.; Potlapalli, Sindhu; McLendon, Kaleb Benjamin; Patel, Anamika; Frank, Filipp; Damhorst, Gregory L.; Wu, Huixia; O’Sick, William Henry; Graciaa, Daniel; Hudaib, Fuad; Alter, David N; Bryksin, Jeannette; Ortlund, Eric A.; Guarner, Jeanette; Auld, Sara; Shah, Sarita; Lam, Wilbur; Mattoon, Dawn; Johnson, Joseph M; Wilson, David H; Dhodapkar, Madhav V.; Stowell, Sean R.; Neish, Andrew S.; Roback, John D.
title: Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against native-like vaccine and delta variant spike trimers
date: 2022-02-16
journal: Res Sq
DOI: 10.21203/rs.3.rs-1322411/v1
sha: 52d6fb2d19c8d7785f1db469f538253920719a4c
doc_id: 774042
cord_uid: as8hve1s

Traditional cellular and live-virus methods for detection of SARS-CoV-2 neutralizing antibodies (nAbs) are labor- and time-intensive, and thus not suited for routine use in the clinical lab to predict vaccine efficacy and natural immune protection. Here, we report the development and validation of a rapid, high throughput method for measuring SARS-CoV-2 nAbs against native-like trimeric spike proteins. This assay uses a blockade of hACE-2 binding (BoAb) approach in an automated digital immunoassay on the Quanterix HD-X platform. BoAb assays using vaccine and delta variant viral strains showed strong correlation with cell-based pseudovirus and live-virus neutralization activity. Importantly, we were able to detect similar patterns of delta variant resistance to neutralization in samples with paired vaccine and delta variant BoAb measurements. Finally, we screened clinical samples from patients with or without evidence of SARS-CoV-2 exposure by a single-dilution screening version of our assays, finding significant nAb activity only in exposed individuals. In principle, these assays offer a rapid, robust, and scalable alternative to time-, skill-, and cost-intensive standard methods for measuring SARS-CoV-2 nAb levels.

Levels of neutralizing antibodies (nAbs) against SARS-CoV-2 and other viruses predict vaccine 38 efficacy and immune protection after natural infection 1-5 . In addition, the degree of protection from 39 sterilizing immunity to prevention of severe disease correlates strongly with nAb levels at any given time 40 post vaccination or infection 6 . Thus, the ability to reliably detect and quantify SARS-CoV-2 nAbs at scale 41 is critical in the ongoing public health effort to reach population level protection in the face of waning 42 immunity and a need for boosters 7 . In addition, the emergence of viral variants that escape neutralization 43 by vaccine-induced antibodies underscores the importance of building efficient and reliable pipelines for 44 nAb assay development as new variants are sequenced and rise to the level of interest or concern (VOI or 45 VOC).

SARS-CoV-2 spike (S) protein is a large homotrimeric glycoprotein, which adopts a metastable 47 prefusion conformation before its high affinity interaction with host-membrane associated angiotensin 48 converting enzyme 2 (ACE-2) 8-10 . Native S protein forms two proteolytically cleaved extracellular subunits 49 (S1 and S2), with S1 containing a specific 222 amino acid (AA) receptor binding domain (RBD) that binds 50 to ACE-2 11-13 . Thus, S1 promotes receptor recognition and high affinity binding. The S2 subunit, in turn, 51 drives membrane fusion through a fusion peptide (FP), two heptad repeat regions (HR1/2), and a 52 transmembrane domain linked to the cytoplasmic tail 14 . To date, studies of neutralizing antibodies elicited 53 by vaccination and natural infection as well as monoclonal antibody therapies have largely focused on 54 antibodies that bind and inhibit interactions through SARS-CoV-2 RBD 15 . However, studies have also 55 identified targets of neutralizing activity in SARS-CoV-2 S protein outside of the RBD, including regions 56 in S2 proximal to the FP and HR2 16 . These findings were recently bolstered in a study by Garrett et al. using 57 phage deep mutation scanning (Phage-DMS) to comprehensively interrogate immunodominant epitopes of 58 antibodies in SARS-CoV-2 convalescent plasma as well as routes of antibody escape by the virus. This 59 study independently identified non-RBD epitopes for neutralizing antibodies in FP and HR2 16 . Together 60 these findings highlight the importance of closely approximating the native structure and domain 61 organization of spike in any robust assay for SARS-CoV-2 neutralizing antibodies.

Current gold-standard assays for measuring nAbs against SARS-CoV-2 require live, replication-63 competent wild virus isolates or infectious molecular clones [17] [18] . While these assays are important tools for 64 research, they require a biosafety level 3 (BSL3) environment, are difficult to standardize, and are poorly 65 suited for any scaled clinical application due to facilities, personnel, and safety requirements. A second tier 66 of widely accepted nAb assays employ replication incompetent reporter viruses-commonly using 67 backbones derived from either HIV or VSV-pseudotyped with SARS-CoV-2 Spike (S) 

To address these limitations, we developed and validated a rapid, high throughput, automated 76 blockade of ACE2 binding (BoAb) assay to quantify SARS-CoV-2 nAb activity against both vaccine 77 (Wuhan-1) and delta (B.1.167.2) variant native-like trimeric spike proteins. This assay is performed on the 78 ultrasensitive Quanterix-HDX platform, and is amenable to routine clinical use. We validated our BoAb by 79 comparison to gold standard live virus and pseudovirus neutralization assays as well as clinically in samples 80 from a cohort of SARS-CoV-2 exposed and vaccinated individuals collected during a serosurvey in the 81 spring of 2021. In principle, our approach offers a rapid, adaptable, and scalable solution for detection of 82 nAbs against any SARS-CoV-2 variant, against other viral pathogens, or against emerging viruses of 83 pathogenic potential.

Detection of SARS-CoV-2 neutralizing antibodies by novel automated assay for blockade of ACE-2 86 binding (BoAb). The majority of SARS-CoV-2 neutralizing antibodies prevent viral entry by inhibiting 87 the biochemical interaction between S protein and ACE-2. We therefore designed our assay to detect 88 inhibition of this interaction by nAbs in patient samples or select inhibitors using SARS-CoV-2 spike 89 conjugated beads as targets for binding by a biotinylated ACE-2 detector (Fig. 1A) . These reagents were 90 then used in a custom three-step assay on the Quanterix HD-X platform (Fig. 1B) . To compare and quantify 91 levels of neutralization from our BoAb assays, we engineered two primary readouts of the assay: an eight-92 point titration to identify the 50% inhibitory dilution or concentration (ID50 or IC50), and a single dilution 93 readout calculated as a percentage of the maximum ACE-2 binding signal for a given spike target bead set.

The latter approach was conceived as a potential screening tool for potent neutralizing antibodies while the 95 former titering approach is appropriate for more rigorous comparisons among subjects or between candidate 96 inhibitors (Fig. 1C) .

In-house generated vaccine strain and delta variant spike proteins adopt native trimeric structures 99 and bind with high affinity to ACE-2. In order to present authentic, native-like spike targets for 100 neutralizing antibody detection, we utilized a soluble, stabilized prefusion spike ectodomain construct 101 originally designed in work by Hsieh et al 23 , but our plasmid DNA sequences are different for WT and 102 Delta strain which were human codon optimized and synthesized at GenScript (Supplementary Text). This 103 construct contains 6 stabilizing proline mutations in S2, which prevent the spontaneous and irreversible 104 formation of a post-fusion state ( Fig. 2A) . Spike targets for vaccine strain (Wuhan-Hu-1 GenBank: 105 MN908947) and delta variant (B.1.617.2) were produced in human 293F cells and purified by affinity and 106 size exclusion chromatography (SEC). A soluble, human IgG Fc chimera of ACE-2 was produced in a 107 similar system before affinity and SEC. Purity of all in-house generated protein reagents was determined 108 to be >95% using reducing SDS-PAGE (Fig. S1) . We studied the structures of purified proteins using 109 negative stain electron microscopy NS-EM (Fig 2 B, C) with 2-dimensional class averaging and found that 110 the proteins are formed in trimers. Further, we confirmed that our spike proteins adopted the expected 111 homotrimeric structures with 3-fold symmetry at the apex and an expected tapering in the S1 to S2 transition 112 ( Fig. 2D, E) . Finally, we confirmed that our ACE-2 detector bound stably and with high affinity to both of 113 these prefusion constructs using biolayer interferometry (Fig. 2F, G) . Both the vaccine strain and delta 114 variant spike reagents bound the ACE2 detector at a similar steady state level and showed stable, slow 115 dissociation rates. Together these data confirm the authentic structure of our spike reagents and their 116 binding activity toward the ACE2 detector used in our BoAb assays. 

( Fig. 3B and 3C) . Similarly, our assay correlated strongly with vaccine strain pseudovirus neutralization 126 activity, particularly in samples above the log ID50 limit of quantification (2.0) for our pseudovirus assay 127 (R 2 = 0.72; P<0.001) (Fig. 3D) . Using this pseudovirus LOQ as a cutoff for positivity, we performed a 128 second ROC analysis and comparing vaccine strain BoAb activity in samples below and above the PNA 

Screening for neutralizing antibody activity by single dilution BoAb among SARS-CoV-2 exposed 156 patients. An ideal clinical screening test for SARS-CoV-2 neutralizing activity, in addition to being 157 automated and well correlated with accepted standard assays, should not require limiting-dilution analysis 158 which carries significant costs associated with skilled labor and resources. We therefore generated a single 159 dilution screening test at a sample dilution that was well correlated with live-virus neutralizing activity

(1:50) (Fig. 5A) . Next, we evaluated the correlation between single-dilution blockade of binding at 1:50 161 with quantitative spike IgG serology, also performed on the Quanterix platform using an EUA serology 162 assay in samples from vaccinated individuals at various times after vaccination. We found a strong linear 163 correlation between blockade of binding and levels of spike IgG in samples with spike specific IgG levels 164 between 5 and 100 µg/mL. At higher concentrations, blockade of binding was saturated at 100% inhibition.

Significant blockade was not detected in samples with less than 5 µg/mL of spike specific IgG (Fig. 5B ).

Finally, the percentage neutralization at a 1:50 dilution was evaluated in a subset of samples from a 167 serosurvey cohort collected in the Emory Healthcare system between January and March of 2021 among 168 inpatients and outpatients who received a blood draw during the relevant encounter. Using available SARS-

CoV-2 PCR testing data and serological results, we categorized patients into individuals more likely to have 170 neutralizing activity at the time of sampling (exposed responders) and those unlikely to have nAb activity showed strong hACE-2 interaction by BLI. 208

For the initial analysis of BoAb assay, we used samples from Nooka et al., 33 who studied 209 the neutralization determinants in myeloma patients. With this cohort, we observed that results in 210 the BoAb assay strongly correlated with both live virus neutralization (Wuhan R 2 = 0.82 and 211 p=<0.001; Delta R 2 = 0.80 and p=<0.001) and pseudovirus neutralization results (Wuhan R 2 = 212 0.72 and p=<0.001; Delta R 2 = 0.66 and p=<0.001). Interestingly, we also identified significant 213 correlation of BoAb results with RBD endpoint titers for both Wuhan (p=<0.001) and Delta strains 214 (p=0.002). These results agree with other studies in which RBD titers are strongly correlated with 215 neutralization titers [34] [35] [36] . In addition, we determined that the BoAb assay showed sensitivity >94% 216 against the Wuhan strain and >90% against Delta strain, both with 100% specificity. In general, 217 neutralization against Delta strain was lower than for Wuhan strain, similarly to results from the 218 BoAb assay. 219

We evaluated the utility of our BoAb assay in a second cohort of samples from a serological 220 survey of patients requiring a blood draw in the Emory Healthcare system from January to March 221 of 2021. We used available COVID-19 PCR testing results and combined serological status to 222 categorize patients who were likely to have been exposed to SARS-CoV-2 and to have developed 223 a humoral immune response against the virus. We hypothesized that this group of exposed 224 responders had the highest pre-test probability in the cohort of harboring SARS-CoV-2 225 neutralizing activity and screened them using a 1:50 single dilution version of our BoAb assay. In 226 agreement with our hypothesis, we observed strong neutralization against SARS-CoV-2 spike that 227 was consistent with the patients' exposure status. Therefore, our data is strongly aligned with 228 correlations of antibody responses vs neutralization responses against SARS-CoV-2 37-39 . The 229 rapid, automated, high-throughput BoAb assay described here may be useful for large-scale 230

It should be noted that our study was limited by availability of gold-standard live-virus neutralizing 232 antibody data and a need to directly correlate activity measured in our assay with known correlates of nAb 233 activity in gold standard cell-based assays. While our data suggest that biochemical neutralization as 234 measured by BoAb correlates well with results from these more established tests, additional work is needed 235 to evaluate the implications of this association for vaccine efficacy and protection after natural infection. 

ACE-2 protein expression and purification. The soluble ACE-2 IgFC chimera was expressed as 288 described above. Clarified supernatants were diluted 1:1 with binding buffer before loading on a protein g 289 gravity flow column, pre-equilibrated with 10 ml of binding buffer (Pierce cat.no.21011). Columns were 290 washed with 20 ml of binding buffer, and the protein was eluted in 40 ml of elution buffer. Following 291 elution, samples were first neutralized to pH 7.5 using 1 M Tris, pH 9.0. Eluted protein was dialyzed against 292 50mM Tris (pH7.5), 150mM NaCl using a Slide-A-lyzer Dialysis Cassette (ThermoScientific, Cat# 66030) 293 and concentrated using 50 kDa Amicon Centrifugal Filter Unit, at 2000 g at 4°C. Size exclusion 294 chromatography and quality control was performed on the concentrated protein as described above.

Assessment of Spike-ACE-2 binding by biolayer interferometry. 6x His-tagged spike was diluted to 50 297 µg/mL in PBS before immobilization on nickel NTA biosensors (fortebio). Association of ACE-2 was 298 monitored using and OctetRED96e instrument (fortebio) in 2-fold dilutions series starting at 100 µg/mL 299 for 600s followed by dissociation in PBS for 500s. Tips were regenerated using 10mM glycine and 300 regenerated in 10 mM NiCl2 before re-loading with equivalent concentrations of spike. Paramagenetic beads were activated after washing with bead conjugation buffer using 9ug EDC (10mg/mL) 314 in a final bead volume of 300 µl containing 4.2E8 beads for 30 minutes at 4 °C with rocking. Following 315 activation, beads were washed with Bead Conjugation Buffer and 300 µl cold spike at 0.2mg/mL to the 316 beads followed by incubation at 4 °C with rocking for 2 hours. Beads were then washed and blocked for 45 317 minutes at room temperature, followed by a final wash and resuspension in 300 µl bead diluent. Spike 318 capture beads were stored at 4 °C until use in the assay.

Negative Stain sample preparation, data collection and data analysis. Spike protein was diluted to 321 0.05mg/ml in PBS prior to grid preparation. A 3 µL drop of diluted protein applied to previously glow-322 discharged, carbon coated grids for ~60 sec, blotted and washed twice with water, stained with 0.75% 

The structural basis of accelerated host cell entry by 398 SARS-CoV-2 †

Evaluation of S-RBD and 402 high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from 403 infection

Structure 406 of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design

Veesler 417 D. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Matsen 422 FA 4th, Overbaugh J. High resolution profiling of pathways of escape for SARS-CoV-2 spike-423 binding antibodies

Quantification of SARS-CoV-2 neutralizing 427 antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus 428 neutralization assays

Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients

Robust neutralization assay based on SARS-CoV-2 S-protein-bearing 441 vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells. Emerg 442 Microbes Infect

Establishment and validation of a pseudovirus 446 neutralization assay for SARS-CoV-2. Emerg Microbes Infect

Development of cell-based pseudovirus entry 449 assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2

A 453 pseudovirus system for the testing of antiviral activity of compounds in different cell lines

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Chapter 7-Functional and Protective Role of Neutralizing Antibodies 463 (NAbs) Against Viral Infections

Antibody responses to viral infections: a structural perspective 466 across three different enveloped viruses

Bloom Humans during a Fishery Vessel Outbreak with a High Attack Rate

Establishment and validation of a pseudovirus 477 neutralization assay for SARS-CoV-2. Emerg Microbes Infect

Neutralization tiers of HIV-1. Curr Opin HIV 480 AIDS

Structure 483 of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Structure and immune recognition of trimeric pre-fusion HIV-1 Env

A Universal Approach 493 to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers

Determinants Of Neutralizing Antibody Response Following SARS CoV-2

Vaccination In Myeloma

Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable 504 Humoral Immunity. Immunity

Sex, age, and 509 hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population

Clin Invest

Potent neutralizing antibodies against multiple epitopes on 515 SARS-CoV-2 spike

Linear regression analysis of vaccine lineage (Wuh-1 & WA1/2020) live virus 50% 611 focus reduction neutralization activity (FRNT50) against ID50s in the vaccine strain BoAb. The absolute 612 value of the log dilution factor at which a sigmoidal curve (fit to duplicate eight-point dilution series for 613 each sample) crossed 50% is plotted for the BoAb assay

Receiver operator characteristic (ROC) curve and 618 categorical comparison of the vaccine strain BoAb using a pseudovirus neutralization ID50 of 2 619 (representing a linear dilution of 1 in 100) as the reference standard for neutralizing activity. (G) Linear 620 regression analysis of vaccine strain (Wuh-1 & WA1/2020) receptor binding domain (RBD) specific IgG 621 titers against IC50s in the vaccine strain BoAb. Values are plotted as in (A) using an optical density cutoff 622 of 0.2 to quantify levels of binding antibodies. (H) Comparison of RBD IgG endpoint titers in samples with 623 vaccine strain BoAb activity less than or greater than a log IC50 of 2

A) Linear regression analysis of delta variant (B.1.617.2) live-virus FRNT 50% inhibitory 644 concentration (ID50) against ID50s in the delta variant BoAb. (B,C) Receiver operator characteristic (ROC) 645 curve and categorical comparison of the delta variant BoAb using a live virus FRNT cutoff of 1.17 (representing a linear dilution of 1 in 15) as the reference standard for neutralizing activity. (D) Linear 647 regression analysis of vaccine strain (Wuh-1 & WA1/2020) pseudovirus 50% inhibitory concentration 648 (ID50) against ID50s in delta variant (B.1.617.2) BoAb. (E,F) Receiver operator characteristic (ROC) curve 649 and categorical comparison of the delta variant BoAb using a pseudovirus neutralization ID50 of 2 650 (representing a linear dilution of 1 in 100) as the reference standard for neutralizing activity. (G) Linear 651 regression analysis of vaccine strain (Wuh-1) receptor binding domain (RBD) specific IgG titers against 652 ID50 values in the delta variant BoAb. Values are plotted as in (A). (H,I) Paired comparison of live virus 653 FRNT50 and BoAb ID50 values between vaccine strain lineage

Screening by linear regression analysis of various single plasma dilution activities (1 to 10, 1 to 20, and 1 to 50) for correlation with WA1/2020 live virus FRNT ID50. R squared values are shown for 662 each regression. (B) Correlation of quantitative anti-spike IgG levels with 1:50 single dilution BoAb in all 663 tested vaccinated individuals. Additionally, the correlation was plotted with a separate linear regression that 664 was limited to samples with inhibition in the linear range (C). Comparison of single dilution delta and 665 vaccine strain neutralizing antibody activity in patients with or without evidence of SARS-CoV-2 exposure 666 and seroconversion from a serosurvey

Statistical significance was evaluated by unpaired non-parametric t tests ns=not significant

Supplementary Figure 1. SDS-PAGE for proteins from SARS-CoV-2 RBD, WT, Delta and hACE-2 672 expressed in Expi293 cells and purified by affinity and size exclusion chromatography